nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-821Research ArticleВСЕМИРНЫЙ ДЕНЬ ПОЧКИ 2011Защищая почки − спасаешь сердцеProtect Your Kidneys, Save Your HeartКаузерУильям Г.CouserWilliam G.noemail@neicon.ruРиеллаМигель К.RiellaMiguel C.noemail@neicon.ruОт объединенного подготовительного комитета Международного общества нефрологов (МОН) и Международной федерации почечных фондов (МФПФ) по проведению Всемирного дня почки 2011 г. Уильям Г. Каузер (МОН), Мигель К. Риелла (МФПФ), сопредседатели. Георги Абрахам, Пол Биркенс, Джон Фили, Гильермо Гарсия Гарсия, Йен Лантик, Дан Ларсен, Филипп Ли, Марк Мэрфи и Бернардо Родригес ИтурбеРоссияWilliam G. Couser (ISN), Miguel C Riella (IFKF), co-chairmen. Georgi Abraham, Paul Beerkens, John Feehally, Guillermo Garcia Garcia, Jan Lantik, Dan Larsen, Philip Li, Mark Murphy and Bernardo Rodriguez-IturbeRussian Federation20111706202513147Copyright © Каузер У.Г., Риелла М.К., 20252025Каузер У.Г., Риелла М.К.Couser W.G., Riella M.C.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/821
Перевод А.К. Цатуряна и И.В. Островской под редакцией Е.В. Захаровой
Всемирный день почкипочкасердечно-сосудистые заболеванияпротеинурияобщественное мнениеReferencesWorld Health Organization. Preventing Chronic Diseases: A Vital Investment: WHO Global Report. 2005. 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes.World Health Organization. Preventing Chronic Diseases: A Vital Investment: WHO Global Report. 2005. 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes.Anderson GF, Chu E. Expanding priorities – Confronting chronic disease in countries with low income.N Engl J Med 356: 209-211, 2007Anderson GF, Chu E. Expanding priorities – Confronting chronic disease in countries with low income.N Engl J Med 356: 209-211, 2007Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases--where worlds meet. N Engl J Med. 363:1196-1198, 2010.Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases--where worlds meet. N Engl J Med. 363:1196-1198, 2010.Ritz E, Bakris G; World Kidney Day Organising Committee.World Kidney Day: hypertension and chronic kidney disease. Lancet. 373:1157-8, 2009Ritz E, Bakris G; World Kidney Day Organising Committee.World Kidney Day: hypertension and chronic kidney disease. Lancet. 373:1157-8, 2009Atkins RC, Zimmet P, ISN-IFKF World Kidney Day Steering Committee. Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol 6:134-136.Atkins RC, Zimmet P, ISN-IFKF World Kidney Day Steering Committee. Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol 6:134-136.Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.351:1296-305, 2004Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.351:1296-305, 2004Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034–2047, 2006Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034–2047, 2006Hillege HL, Fidler V, Diercks GFH, Gilst WH van, Zeeuw D de, Veldhuisen DJ van, Gans ROB, Janssen WMT, Grobbee DE, Jong PE de; for the PREVEND study group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation; 106:1777-82, 2002Hillege HL, Fidler V, Diercks GFH, Gilst WH van, Zeeuw D de, Veldhuisen DJ van, Gans ROB, Janssen WMT, Grobbee DE, Jong PE de; for the PREVEND study group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation; 106:1777-82, 2002Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circ 110:32-35, 2004.Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circ 110:32-35, 2004.van Domburg RT, Hoeks SE, Welten GMJM, Chonchol M, Elhendy A, Poldermans D.Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Neph 19:158-163, 2008van Domburg RT, Hoeks SE, Welten GMJM, Chonchol M, Elhendy A, Poldermans D.Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Neph 19:158-163, 2008Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol. 102:1668-7, 2008Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol. 102:1668-7, 2008McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JA, Whaley-Connell AT; Kidney Early Evaluation Program Investigators. CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Ds 51, S38-S45, 2008McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JA, Whaley-Connell AT; Kidney Early Evaluation Program Investigators. CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Ds 51, S38-S45, 2008McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 167:1122-1129, 2007McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 167:1122-1129, 2007McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Whaley-Connell AT, Brenner RM, Bakris GL; KEEP Investigators.Chronic kidney disease: prevalence of premature cardiovascular disease and relationship to short-term mortality.Am Heart J. 156:277-83, 2008.McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Whaley-Connell AT, Brenner RM, Bakris GL; KEEP Investigators.Chronic kidney disease: prevalence of premature cardiovascular disease and relationship to short-term mortality.Am Heart J. 156:277-83, 2008.Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.Am J Epidemiol;167, 1226-33, 2008Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.Am J Epidemiol;167, 1226-33, 2008Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.Kidney Int. 69:1264-71, 2006Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.Kidney Int. 69:1264-71, 2006Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators Individuals at Increased renal risk. J Amer Soc Nephrol 20:852-862, 2009Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators Individuals at Increased renal risk. J Amer Soc Nephrol 20:852-862, 2009Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M; Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial.BMJ. 332:1426, 2006Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M; Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial.BMJ. 332:1426, 2006Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in estimated GFR associates with coronary heart disease and mortality.J Am Soc Nephrol. 20:2617-24, 2009Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in estimated GFR associates with coronary heart disease and mortality.J Am Soc Nephrol. 20:2617-24, 2009Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki SMalyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. Prevalence of Chronic Kidney Disease in Elderly Patients with Normal Serum Creatinine Levels Undergoing Percutaneous Coronary Interventions. Gerontol 56:51-54, 2010Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki SMalyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. Prevalence of Chronic Kidney Disease in Elderly Patients with Normal Serum Creatinine Levels Undergoing Percutaneous Coronary Interventions. Gerontol 56:51-54, 2010Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M; Alberta Kidney Disease Network.Relation between kidney function, proteinuria, and adverse outcomes.JAMA. 303:423-9, 2010Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M; Alberta Kidney Disease Network.Relation between kidney function, proteinuria, and adverse outcomes.JAMA. 303:423-9, 2010Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Amer Soc Nephrol. 20:465-68, 2009Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Amer Soc Nephrol. 20:465-68, 2009Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081, 2010Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081, 2010Abdelhafiz AH, Brown SH, Bello A, El Nahas M Chronic kidney disease in older people: physiology, pathology or both?Nephron Clin Pract.;116:19-24. 2010.Abdelhafiz AH, Brown SH, Bello A, El Nahas M Chronic kidney disease in older people: physiology, pathology or both?Nephron Clin Pract.;116:19-24. 2010.Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyBrenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyRuggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999.Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999.Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 352:1252-1256, 1998Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 352:1252-1256, 1998The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1857-63, 1997The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1857-63, 1997The ESCAPE trial group: Strict blood pressure control and progression of renal failure in children. New Engl J Med 361:1639-1650, 2009The ESCAPE trial group: Strict blood pressure control and progression of renal failure in children. New Engl J Med 361:1639-1650, 2009Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH, Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation110 : 2809 –2816, 2004Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH, Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation110 : 2809 –2816, 2004Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVEND IT Study Group.Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther. 28:432-444, 2006Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVEND IT Study Group.Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther. 28:432-444, 2006de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Brenner BM: Albuminuria: a therapeutic target for cardiovascular protection in type 2 diabetic nephropathy. Circulation110 : 921 –927, 2004.de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Brenner BM: Albuminuria: a therapeutic target for cardiovascular protection in type 2 diabetic nephropathy. Circulation110 : 921 –927, 2004.Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in type II diabetic patients with nephropathy. Post hoc analysis from the Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18:1540-1546, 2007Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in type II diabetic patients with nephropathy. Post hoc analysis from the Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18:1540-1546, 2007Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease.J Am Soc Nephrol.20:893-900, 2009Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease.J Am Soc Nephrol.20:893-900, 2009Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 19:999-1007, 2008Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 19:999-1007, 2008Fried L. Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 20:686-688, 2009Fried L. Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 20:686-688, 2009El Nahas M. the global challenge of chronic kidney disease. (Nephrology Forum) Kidney Int 68:2918-2929, 2005.El Nahas M. the global challenge of chronic kidney disease. (Nephrology Forum) Kidney Int 68:2918-2929, 2005.Barsoum RS. Chronic Kidney disease in the developing world. New Engl J Med 354:997-999, 2006Barsoum RS. Chronic Kidney disease in the developing world. New Engl J Med 354:997-999, 2006Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W; Centers for Disease Control and Prevention Expert Panel. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 53:522-535, 2009Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W; Centers for Disease Control and Prevention Expert Panel. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 53:522-535, 2009James MT, Hemmelgarn, BR, Tonelli, M. Early recognition and prevention of CKD. Lancet 379:1296-1309, 2010.James MT, Hemmelgarn, BR, Tonelli, M. Early recognition and prevention of CKD. Lancet 379:1296-1309, 2010.Perico N, Bravo RF, De Leon FR, Remuzzi G. Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrol Dial Transplant. 24:1355-1358, 2009Perico N, Bravo RF, De Leon FR, Remuzzi G. Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrol Dial Transplant. 24:1355-1358, 2009
The authors declare that there are no conflicts of interest present.